NASDAQ:AGEN Agenus (AGEN) Stock Price, News & Analysis $3.11 +0.25 (+8.74%) Closing price 05/2/2025 04:00 PM EasternExtended Trading$3.13 +0.02 (+0.51%) As of 05/2/2025 07:44 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock About Agenus Stock (NASDAQ:AGEN) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Agenus alerts:Sign Up Key Stats Today's Range$2.89▼$3.1950-Day Range$1.51▼$3.1452-Week Range$1.38▼$19.69Volume904,613 shsAverage Volume579,091 shsMarket Capitalization$78.71 millionP/E RatioN/ADividend YieldN/APrice Target$8.75Consensus RatingHold Company OverviewAgenus Inc., a clinical-stage biotechnology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies. It develops QS-21 Stimulon adjuvant, a saponin-based vaccine adjuvant. The company also develops Balstilimab, an anti-PD-1 antagonist that has completed Phase II clinical trial to treat second line cervical cancer; AGEN1181, an antigen 4 (CTLA-4) blocking antibody that is in Phase 2 clinical trial for the treatment of pancreatic cancer and and melanoma; AGEN2373, a CD137 monospecific antibody that is in Phase 1b clinical trial; AGEN1423, a CD73/TGFß TRAP antibody; AGEN1571, an ILT2 monospecific antibody that is in Phase 1 clinical trial; and BMS-986442, a TIGIT bispecific antibodies. In addition, it develops INCAGN1876, a GITR agonist; INCAGN2390, a TIM-3 monospecific antibody; INCAGN2385, a LAG-3 monospecific antibody; MK-4830, a monospecific antibody targeting ILT4 that is in Phase 2 clinical trial; UGN-301, a zalifrelimab intravesical solution for the treatment of cancers of the urinary tract that is in a Phase 1 clinical trial; and AGEN1884, a first-generation anti-CTLA-4 monospecific antibody. The company operates under Agenus, MiNK, Prophage, Retrocyte Display, and Stimulon trademarks. It has collaborations with Bristol-Myers Squibb Company, Betta Pharmaceuticals Co., Ltd., Incyte Corporation, Merck Sharpe & Dohme, and Gilead Sciences, Inc. The company was formerly known as Antigenics Inc. and changed its name to Agenus Inc. in January 2011. Agenus Inc. was founded in 1994 and is headquartered in Lexington, Massachusetts.Read More… Agenus Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks69th Percentile Overall ScoreAGEN MarketRank™: Agenus scored higher than 69% of companies evaluated by MarketBeat, and ranked 299th out of 916 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.1 / 5Analyst RatingHold Consensus RatingAgenus has received a consensus rating of Hold. The company's average rating score is 2.17, and is based on 1 buy rating, 5 hold ratings, and no sell ratings.Amount of Analyst CoverageAgenus has only been the subject of 3 research reports in the past 90 days.Read more about Agenus' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Agenus are expected to grow in the coming year, from ($12.55) to ($7.16) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Agenus is -0.28, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Agenus is -0.28, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about Agenus' valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted16.76% of the float of Agenus has been sold short.Short Interest Ratio / Days to CoverAgenus has a short interest ratio ("days to cover") of 7.9.Change versus previous monthShort interest in Agenus has recently increased by 9.55%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldAgenus does not currently pay a dividend.Dividend GrowthAgenus does not have a long track record of dividend growth. Sustainability and ESG4.6 / 5Environmental Score-0.93 Percentage of Shares Shorted16.76% of the float of Agenus has been sold short.Short Interest Ratio / Days to CoverAgenus has a short interest ratio ("days to cover") of 7.9.Change versus previous monthShort interest in Agenus has recently increased by 9.55%, indicating that investor sentiment is decreasing significantly. News and Social Media1.7 / 5News Sentiment0.14 News SentimentAgenus has a news sentiment score of 0.14. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.65 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 8 news articles for Agenus this week, compared to 6 articles on an average week.Search InterestOnly 10 people have searched for AGEN on MarketBeat in the last 30 days. This is a decrease of -33% compared to the previous 30 days.MarketBeat FollowsOnly 6 people have added Agenus to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Agenus insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 4.60% of the stock of Agenus is held by insiders.Percentage Held by Institutions61.46% of the stock of Agenus is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Agenus' insider trading history. Receive AGEN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Agenus and its competitors with MarketBeat's FREE daily newsletter. Email Address AGEN Stock News HeadlinesHC Wainwright Reiterates "Neutral" Rating for Agenus (NASDAQ:AGEN)May 3 at 2:45 AM | americanbankingnews.comAgenus to Provide Corporate Update and First Quarter 2025 Financial ReportApril 29, 2025 | finance.yahoo.comBuffett’s favorite chart just hit 209% – here’s what that means for goldA Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the quiet buildup behind the scenes. Now, in just days, the floodgates are set to open. The greatest investor of all time is about to validate what Garrett Goggin has been saying for months: Gold is entering a once-in-a-generation mania. Front-running Buffett has never been more urgent — and four tiny miners could be your ticket to 100X gains.May 4, 2025 | Golden Portfolio (Ad)Agenus’ BOT/BAL Neoadjuvant Pan-Cancer Data from the NEOASIS Study Presented in an Oral Session at AACRApril 28, 2025 | finance.yahoo.comAgenus' BOT/BAL Neoadjuvant Pan-Cancer Data from the NEOASIS Study Presented in an Oral Session at AACRApril 28, 2025 | businesswire.comEquities Analysts Offer Predictions for Agenus Q1 EarningsApril 26, 2025 | americanbankingnews.comAgenus' BOT/BAL Data in Pretreated Liver Cancer Presented at AACR 2025 | AGEN Stock NewsApril 25, 2025 | gurufocus.comAgenus' BOT/BAL Data in Pretreated Liver Cancer Presented at AACR 2025April 25, 2025 | gurufocus.comSee More Headlines AGEN Stock Analysis - Frequently Asked Questions How have AGEN shares performed this year? Agenus' stock was trading at $2.74 at the beginning of the year. Since then, AGEN shares have increased by 13.5% and is now trading at $3.11. View the best growth stocks for 2025 here. How were Agenus' earnings last quarter? Agenus Inc. (NASDAQ:AGEN) posted its earnings results on Tuesday, March, 11th. The biotechnology company reported ($2.04) earnings per share (EPS) for the quarter, beating the consensus estimate of ($2.36) by $0.32. The biotechnology company had revenue of $26.84 million for the quarter, compared to analyst estimates of $30.09 million. Read the conference call transcript. When did Agenus' stock split? Shares of Agenus reverse split on Friday, April 12th 2024. The 1-20 reverse split was announced on Friday, April 12th 2024. The number of shares owned by shareholders was adjusted after the market closes on Friday, April 12th 2024. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. Who are Agenus' major shareholders? Agenus' top institutional investors include Apollon Wealth Management LLC (0.10%). Insiders that own company stock include Agenus Inc and Garo H Armen. View institutional ownership trends. How do I buy shares of Agenus? Shares of AGEN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Agenus own? Based on aggregate information from My MarketBeat watchlists, some other companies that Agenus investors own include DiamondRock Hospitality (DRH), Waste Connections (WCN), American Water Works (AWK), Voyager Therapeutics (VYGR), The RMR Group (RMR), AUO (AUOTY) and iShares Micro-Cap ETF (IWC). Company Calendar Last Earnings3/11/2025Today5/04/2025Next Earnings (Estimated)5/12/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryBiotechnology Current SymbolNASDAQ:AGEN CIK1098972 Webagenusbio.com Phone(781) 674-4400Fax781-674-4200Employees440Year FoundedN/APrice Target and Rating Average Stock Price Target$8.75 High Stock Price Target$18.00 Low Stock Price Target$3.00 Potential Upside/Downside+181.4%Consensus RatingHold Rating Score (0-4)2.17 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)($10.68) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-245,760,000.00 Net Margins-145.89% Pretax Margin-145.89% Return on EquityN/A Return on Assets-85.68% Debt Debt-to-Equity RatioN/A Current Ratio0.19 Quick Ratio0.19 Sales & Book Value Annual Sales$103.46 million Price / Sales0.76 Cash FlowN/A Price / Cash FlowN/A Book Value($7.78) per share Price / Book-0.40Miscellaneous Outstanding Shares25,309,000Free Float22,380,000Market Cap$78.71 million OptionableOptionable Beta1.58 Social Links Reduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.Get This Free Report This page (NASDAQ:AGEN) was last updated on 5/4/2025 by MarketBeat.com Staff From Our PartnersThink NVDA’s run was epic? You ain’t seen nothin’ yetAsk most investors and they’ll probably tell you Nvidia is the undisputed AI stock of the decade. In 2023, ...Timothy Sykes | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredAltucher: Turn $900 into $108,000 in just 12 months?We are entering the final Trump Bump of our lives. But the biggest returns will not be in the stock market.Paradigm Press | SponsoredTrump to redistribute trillions of dollars Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredElon’s Terrifying Warning Forces Trump To Take ActionElon Musk has avoided two major financial crises before. He pulled Tesla and SpaceX back from the brink of col...American Hartford Gold | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Robots aren't coming to America in 2025. They are already here. Oxford Economics says, "The Robotics Rev...Weiss Ratings | SponsoredIf you missed your chance with Tesla...Elon Musk is moments from launching a revolutionary technology some Silicon Valley insiders are calling "The F...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Agenus Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Agenus With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.